KNSAKiniksa Pharmaceuticals International, plc
$76.71+97% 1Y
$76.71
$37.0152 weeks$83.18
The financials
Kiniksa Pharmaceuticals International, plc by the numbers
Kiniksa Pharmaceuticals International, plc (KNSA) reported revenue of $244M in Q2 2026 (quarter ended Jun 30, 2026), up 55% from the same quarter a year earlier. That came with a gross margin of 90% and net income of $25M (10% of revenue). For the full year FY2025, revenue was $678M (+60% year on year) and net income $59M. The next results filing is expected around Oct 27, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $244M | $157M | +55% |
| Gross profit | $220M | $138M | +59% |
| Operating income | $27M | $20M | +35% |
| Net income | $25M | $18M | +43% |
| Diluted EPS | $0.30 | $0.23 | +30% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $0.00
Segment Latestyear on year
- Collaboration$0.00$0.00year on year n/an/a
Drug Manufacturers, Specialty & Generic
Ranks #30 of 39 by RyuScore